{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T07:35:23Z","timestamp":1774596923343,"version":"3.50.1"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82571592, 82471426"],"award-info":[{"award-number":["82571592, 82471426"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Predicting exacerbation risk in clinically treated patients with myasthenia gravis (MG) is essential for personalised intervention with neurotherapies. This study investigated whether dynamic monitoring of anti-acetylcholine receptor antibody (AChR-ab) levels could predict exacerbation in MG patients following minimal symptom expression (MSE), and developed a validated model for risk stratification to inform treatment decisions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a bicenter cohort study enrolling AChR-ab+ adult MG patients who achieved MSE. The derivation cohort included 339 patients from Huashan Hospital, and the validation cohort comprised 60 patients from West China Hospital. Exacerbation was defined as an increase of \u2265 2 points in the MG Activities of Daily Living score. Independent predictors were identified through univariate and multivariate logistic regression analyses, and a prediction model was subsequently developed and validated using discrimination and calibration metrics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Longitudinal AChR-ab levels strongly correlated with disease progression, with a median time to exacerbation of 35.1 months post-MSE. Independent predictors included disease duration to MSE achievement, AChR-ab change, thymoma, comorbid immune-related diseases, and history of myasthenic crisis. The model demonstrated excellent discrimination in derivation (AUC = 0.886) and validation cohorts (AUC = 0.829), with good calibration in both datasets.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Dynamic AChR-ab monitoring provides strong predictive value for MG exacerbation, and our validated prediction model offers clinicians a practical tool for personalized risk stratification and therapeutic decision-making in patients achieving disease stability.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1786218","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T06:37:58Z","timestamp":1774593478000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictors of exacerbation in myasthenia gravis after minimal symptom expression: a bicenter cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Dingxian","family":"He","sequence":"first","affiliation":[{"name":"Huashan Rare Disease Centre and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Centre for Neurological Disorders, Fudan University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huahua","family":"Zhong","sequence":"additional","affiliation":[{"name":"Huashan Rare Disease Centre and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Centre for Neurological Disorders, Fudan University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nana","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong","family":"Yan","sequence":"additional","affiliation":[{"name":"Huashan Rare Disease Centre and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Centre for Neurological Disorders, Fudan University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Song","sequence":"additional","affiliation":[{"name":"Huashan Rare Disease Centre and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Centre for Neurological Disorders, Fudan University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianying","family":"Xi","sequence":"additional","affiliation":[{"name":"Huashan Rare Disease Centre and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Centre for Neurological Disorders, Fudan University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sushan","family":"Luo","sequence":"additional","affiliation":[{"name":"Huashan Rare Disease Centre and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Centre for Neurological Disorders, Fudan University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chongbo","family":"Zhao","sequence":"additional","affiliation":[{"name":"Huashan Rare Disease Centre and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Centre for Neurological Disorders, Fudan University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyu","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Neurology, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00776","article-title":"Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology","volume":"11","author":"Fichtner","year":"2020","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2020.100063","article-title":"Incidence, mortality, and economic burden of myasthenia gravis in China: a nationwide population-based study","volume":"5","author":"Chen","year":"2020","journal-title":"Lancet Reg Health West Pac"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10891-1","article-title":"Burden of disease in myasthenia gravis: taking the patient's perspective","volume":"269","author":"Lehnerer","year":"2022","journal-title":"J Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.816243","article-title":"Clinical predictors of relapse in a cohort of steroid-treated patients with well-controlled myasthenia gravis","volume":"13","author":"Su","year":"2022","journal-title":"Front Neurol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2006.00609.x","article-title":"Myasthenia gravis: disease severity and prognosis","volume":"183","author":"Romi","year":"2006","journal-title":"Acta Neurol Scand Suppl"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2025.2475075","article-title":"Economic burden of myasthenia gravis in China: a nationwide registry-based study","volume":"41","author":"Yu","year":"2025","journal-title":"Curr Med Res Opin"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419832242","article-title":"Understanding the burden of refractory myasthenia gravis","volume":"12","author":"Schneider-Gold","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1007\/s00415-020-09770-y","article-title":"Minimal symptom expression\" in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab","volume":"267","author":"Vissing","year":"2020","journal-title":"J Neurol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1007\/s00415-025-13476-4","article-title":"Association between antibody status and exacerbation in patients with myasthenia gravis who achieved minimal manifestation or better status","volume":"272","author":"Li","year":"2025","journal-title":"J Neurol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2025.40.e240","article-title":"Identification of high-risk population for mortality and severe clinical outcomes among patients with myasthenia gravis: a nationwide population-based cohort study in Korea","volume":"40","author":"Woo","year":"2025","journal-title":"J Korean Med Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16522","article-title":"Intensive care due to myasthenia gravis: risk factors and prognosis","volume":"31","author":"Myllynen","year":"2024","journal-title":"Eur J Neurol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1177\/20406223221122538","article-title":"Remission and relapses of myasthenia gravis on long-term tacrolimus: a retrospective cross-sectional study of a Chinese cohort","volume":"13","author":"Bi","year":"2022","journal-title":"Ther Adv Chronic Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25087","article-title":"A clinical predictive score for postoperative myasthenic crisis","volume":"82","author":"Kanai","year":"2017","journal-title":"Ann Neurol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e41084","article-title":"Predictive modeling and interpretative analysis of risks of instability in patients with myasthenia gravis requiring intensive care unit admission","volume":"10","author":"Kuo","year":"2024","journal-title":"Heliyon"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.895007","article-title":"Development and validation of a nomogram for predicting generalization in patients with ocular myasthenia gravis","volume":"13","author":"Ruan","year":"2022","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1177\/17562864231154976","article-title":"Short-term outcome prediction for myasthenia gravis: an explainable machine learning model","volume":"16","author":"Zhong","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1177\/1756286420935697","article-title":"C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis","volume":"13","author":"Aguirre","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01074","article-title":"Role of miRNAs in normal and myasthenia gravis thymus","volume":"11","author":"Cron","year":"2020","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2024.119873","article-title":"Serum metabolomic profile of myasthenia gravis and potential values as biomarkers in disease monitoring","volume":"562","author":"Sha","year":"2024","journal-title":"Clin Chim Acta"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2023.578205","article-title":"Serum cytokine profiles in myasthenia gravis with anti-muscle-specific kinase antibodies","volume":"384","author":"Yasuda","year":"2023","journal-title":"J Neuroimmunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00212","article-title":"Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front Immunol"},{"key":"B22","article-title":"Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3","volume":"67","author":"Rodgaard","year":"1987","journal-title":"Clin Exp Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.29271\/jcpsp.2021.08.965","article-title":"Relationship between low and high anti-acetylcholine receptor antibody titers and clinical severity in myasthenia gravis","volume":"31","author":"Ullah","year":"2021","journal-title":"J Coll Physicians Surg Pak"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23944","article-title":"Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis","volume":"49","author":"Sanders","year":"2014","journal-title":"Muscle Nerve"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010910","article-title":"Improving accuracy of myasthenia gravis autoantibody testing by reflex algorithm","volume":"95","author":"Shelly","year":"2020","journal-title":"Neurology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0114060","article-title":"Repeated acetylcholine receptor antibody-concentrations and association to clinical myasthenia gravis development","volume":"9","author":"Heldal","year":"2014","journal-title":"PloS One"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1053\/j.semtcvs.2019.09.002","article-title":"Risk factors for the exacerbation of myasthenic symptoms after surgical therapy for myasthenia gravis and thymoma","volume":"32","author":"Kato","year":"2020","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-325511","article-title":"Rate of change in acetylcholine receptor antibody levels predicts myasthenia gravis outcome","volume":"92","author":"Kojima","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/0090-1229(77)90027-7","article-title":"An assay for antibodies to human acetylcholine receptor in serum from patients with myasthenia gravis","volume":"7","author":"Lindstrom","year":"1977","journal-title":"Clin Immunol Immunopathol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1177249","article-title":"Clinical and immune-related factors associated with exacerbation in adults with well-controlled generalized myasthenia gravis","volume":"14","author":"Bi","year":"2023","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27497","article-title":"Clinical course and outcome of an outpatient clinic population with myasthenia gravis and COVID-19","volume":"65","author":"Gungor Tuncer","year":"2022","journal-title":"Muscle Nerve"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-022-02162-1","article-title":"Minimal symptom expression achievement over time in generalized myasthenia gravis","volume":"123","author":"Uzawa","year":"2023","journal-title":"Acta Neurol Belg"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1097\/00131402-200209000-00009","article-title":"On the concept of myasthenic crisis","volume":"4","author":"Bedlack","year":"2002","journal-title":"J Clin Neuromuscul Dis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000003570","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-024-07368-0","article-title":"Comorbidity in myasthenia gravis: multicentric, hospital-based, and controlled study of 178 Italian patients","volume":"45","author":"Di Stefano","year":"2024","journal-title":"Neurol Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.4103\/0972-2327.44560","article-title":"Myasthenia gravis and acetylcholine receptor antibodies: a clinico immunological correlative study on South Indian patients","volume":"11","author":"Bindu","year":"2008","journal-title":"Ann Indian Acad Neurol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1097\/cnd.0b013e31828a0090","article-title":"Correlation between acetylcholine receptor antibody levels and thymic pathology in myasthenia gravis: a review","volume":"14","author":"Huang","year":"2013","journal-title":"J Clin Neuromuscul Dis"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1506845","article-title":"Exploring the clinical significance of anti-acetylcholine receptor antibody titers, changes, and change rates in myasthenia gravis","volume":"15","author":"Luo","year":"2024","journal-title":"Front Neurol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-015-0398-y","article-title":"Current treatment, emerging translational therapies, and new therapeutic targets for autoimmune myasthenia gravis","volume":"13","author":"Guptill","year":"2016","journal-title":"Neurotherapeutics"},{"key":"B41","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s12026-012-8345-z","article-title":"Linking complement and anti-dsDNA antibodies in the pathogenesis of systemic lupus erythematosus","volume":"55","author":"Giles","year":"2013","journal-title":"Immunol Res"},{"key":"B42","article-title":"Changes in anti-cyclic citrullinated peptide antibodies and rheumatoid factor isotypes serum levels in patients with rheumatoid arthritis following treatment with different biological drugs","volume":"34","author":"Iannone","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-010-1557-5","article-title":"The continuous measurement of anti-CCP-antibodies does not help to evaluate the disease activity in anti-CCP-antibody-positive patients with rheumatoid arthritis","volume":"29","author":"Landmann","year":"2010","journal-title":"Clin Rheumatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8090312","article-title":"Longitudinal serum neurofilament levels of multiple sclerosis patients before and after treatment with first-line immunomodulatory therapies","volume":"8","author":"Huss","year":"2020","journal-title":"Biomedicines"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/0960-8966(91)90005-d","article-title":"Azathioprine in myasthenia gravis: observations in 41 patients and a review of literature","volume":"1","author":"Kuks","year":"1991","journal-title":"Neuromuscul Disord NMD"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2025.103517","article-title":"Humoral correlates of clinical response to thymectomy in myasthenia gravis","volume":"158","author":"Sousa","year":"2026","journal-title":"J Autoimmun"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2020.03.81","article-title":"Subxiphoid completion thymectomy for refractory non-thymomatous myasthenia gravis","volume":"12","author":"Ambrogi","year":"2020","journal-title":"J Thorac Dis"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1590\/0004-282x20130108","article-title":"The myasthenic patient in crisis: an update of the management in neurointensive care unit","volume":"71","author":"Godoy","year":"2013","journal-title":"Arq Neuropsiquiatr"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1288045","article-title":"Autoimmunity in thymic epithelial tumors: a not yet clarified pathologic paradigm associated with several unmet clinical needs","volume":"15","author":"Perrino","year":"2024","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51312","article-title":"In-depth peripheral CD4+ T profile correlates with myasthenic crisis","volume":"8","author":"Huan","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3109\/08916934.2015.1030614","article-title":"Complicating autoimmune diseases in myasthenia gravis: a review","volume":"48","author":"Nacu","year":"2015","journal-title":"Autoimmunity"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1786218\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T06:37:59Z","timestamp":1774593479000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1786218\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":51,"alternative-id":["10.3389\/fimmu.2026.1786218"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1786218","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"article-number":"1786218"}}